A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) with a recent average price target of $100.7. The company's financials show positive revenue growth and strong profitability metrics, but its growth rate lags behind industry peers.
July 22, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical has received mixed ratings from analysts, with an average price target of $100.7. The company's financials show positive revenue growth and strong profitability metrics, but its growth rate lags behind industry peers.
The mixed analyst ratings and slight decline in the average price target suggest a neutral short-term impact on BMRN's stock price. While the company shows strong profitability and positive revenue growth, its growth rate lags behind industry peers, balancing the overall sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100